Star Equity (STRR) 10-Q 1 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 24, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	DIGIRAD CORP
Entity Central Index Key	707388
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		19,243,445

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Comprehensive Income (Loss) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Diagnostic Services	$10,563	$9,555
Diagnostic Imaging	3,276	3,442
Total revenues	13,839	12,997
Cost of revenues:
Diagnostic Services	8,505	7,534
Diagnostic Imaging	1,686	2,021
Total cost of revenues	10,191	9,555
Gross profit	3,648	3,442
Operating expenses:
Marketing and sales	1,210	1,095
General and administrative	2,168	1,995
Amortization of intangible assets	105	66
Restructuring charges	0	441
Total operating expenses	3,483	3,597
Income (loss) from operations	165	-155
Interest and other income, net
Interest and other income, net	11	17
Interest expense	-11	-8
Total other income	0	9
Income (loss) before income taxes	165	-146
Income tax benefit (expense)	580	-2
Net income (loss)	745	-148
Net income (loss) per share - basic (in dollars per share)	$0.04	($0.01)
Net income (loss) per share - diluted (in dollars per share	$0.04	($0.01)
Weighted average shares outstanding – basic	18,803	18,518
Weighted average shares outstanding – diluted	19,291	18,518
Dividends declared per common share (in US$ per share)	$0.05	$0.05
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	14	-18
Total other comprehensive income (loss)	14	-18
Comprehensive income (loss)	$759	($166)

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015		Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$13,876		$14,051
Securities available-for-sale	7,048		7,935
Accounts receivable, net	7,060		5,989
Inventories, net	3,657		3,644
Other current assets	898		856
Restricted cash	477		477
Total current assets	33,016		32,952
Property and equipment, net	5,197		4,766
Intangible assets, net	3,479		2,577
Goodwill	2,889	[1],[2]	1,337
Other assets	289		269
Total assets	44,870		41,901
Liabilities and stockholders’ equity
Accounts payable	2,242		1,423
Accrued compensation	2,587		3,261
Accrued warranty	159		176
Deferred revenue	1,481		1,644
Other accrued liabilities	2,086		1,789
Total current liabilities	8,555		8,293
Other liabilities	966		963
Total liabilities	9,521		9,256
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	0		0
Common stock, $0.0001 par value: 80,000,000 shares authorized; 19,240,945 and 18,615,945 shares issued and outstanding (net of treasury shares) at March 31, 2015 and December 31, 2014, respectively	2		2
Treasury stock, at cost; 2,588,484 shares at March 31, 2015 and December 31, 2014	-5,728		-5,728
Additional paid-in capital	155,714		153,769
Accumulated other comprehensive loss	-5		-19
Accumulated deficit	-114,634		-115,379
Total stockholders’ equity	35,349		32,645
Total liabilities and stockholders’ equity	$44,870		$41,901
[1]	mortization expense for intangible assets, net was $0.1 million for the three months ended March 31, 2015 and 2014. Estimated amortization expense for intangible assets for the remainder of 2015 is $0.4 million, for 2016 is $0.5 million, for 2017 is $0.5 million, for 2018 is $0.5 million, for 2019 is $0.4 million, for 2020 is $0.4 million, and thereafter is $0.8 million.
[2]	.

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	19,240,945	18,615,945
Common stock, shares outstanding	19,240,945	18,615,945
Treasury stock, shares	2,558,484	2,588,484

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating activities
Net income (loss)	$745	($148)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation	383	387
Amortization of intangible assets	105	66
Provision for bad debt	37	21
Stock-based compensation	144	50
(Gain) loss on sale of assets	-17	5
Amortization of premiums on investments	36	51
Changes in operating assets and liabilities:
Accounts receivable	-665	-1,699
Inventories	-13	293
Other assets	-6	70
Accounts payable	670	449
Accrued compensation	-755	-1,019
Deferred revenue	-163	-250
Other liabilities	-379	168
Restricted cash	0	-233
Net cash provided by (used in) operating activities	122	-1,789
Investing activities
Purchases of property and equipment	-211	-571
Net proceeds from sale of assets	17	0
Purchases of securities available-for-sale	0	-2,617
Maturities of securities available-for-sale	865	350
Net cash received from (paid for) acquisition	3	-3,470
Net cash provided by (used in) investing activities	674	-6,308
Financing activities
Issuances of common stock	48	0
Dividends paid	-931	-925
Repayment of long-term debt	0	-131
Repayment of obligations under capital leases	-88	-42
Net cash used in financing activities	-971	-1,098
Net decrease in cash and cash equivalents	-175	-9,195
Cash and cash equivalents at beginning of period	14,051	18,744
Cash and cash equivalents at end of period	13,876	9,549
Noncash or Part Noncash Acquisition, Fixed Assets Acquired	122	54
Stock Issued During Period, Value, Acquisitions	$2,684	$0

The_Company

The Company	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	The Company
	Digirad Corporation ("Digirad"), a Delaware corporation, is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services, and also provides cardiac event monitoring services. These services are provided to physician practices, hospitals, and imaging centers through our Diagnostic Services reportable segment. Digirad also sells solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products sold, through our Diagnostic Imaging reportable segment. These two reportable segments, Diagnostic Services and Diagnostic Imaging, are collectively referred to herein as the “Company.”
	The accompanying condensed consolidated financial statements include the operations of both segments. Intercompany accounts and transactions are accounted for at cost and have been eliminated in consolidation. All our long-lived assets are located in the United States and substantially all of our revenues arise from sales activity in the United States.
	Basis of Presentation
	The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (SEC) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (GAAP) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2014, filed with the SEC on Form 10-K on March 6, 2015, include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows, and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.
	Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates.
	The financial results for the three months ended March 31, 2015 include the financial results of MD Office Solutions and Telerhythmics, LLC. See Note 3 to the unaudited condensed consolidated financial statements for more information related to the acquisition of MD Office Solutions and Telerhythmics, LLC.
	Recent Accounting Pronouncement
	In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers which supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. The guidance allows for either full retrospective or modified retrospective adoption and is currently scheduled to become effective for us in the first quarter of 2017. On April 1, 2015, the FASB voted to propose a one-year deferral to the effective date, but to permit entities to adopt one year earlier if they choose (i.e., the original effective date). We are currently evaluating the alternative transition methods and the potential effects of the adoption of this guidance on our financial statements.

Basic_and_Diluted_Net_Income_L

Basic and Diluted Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share, Basic and Diluted [Abstract]
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share
	For the three months ended March 31, 2015 and 2014, basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares and vested restricted stock units outstanding during the period. Diluted net income (loss) per common share is calculated to give effect to all dilutive securities, if applicable, using the treasury stock method.
	The following table sets forth the reconciliation of shares used to compute basic and diluted net income (loss) per share for the periods indicated:
		Three Months Ended March 31,
	(shares in thousands)	2015	2014
	Weighted average shares outstanding - basic	18,803	18,518
	Dilutive potential common stock outstanding:
	Stock options	474	—
	Restricted stock units	14	—
	Weighted average shares outstanding - diluted	19,291	18,518
	The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net income (loss) per share because their effect was anti-dilutive:
		Three Months Ended March 31,
	(shares in thousands)	2015	2014
	Stock options	3	373
	Restricted stock units	—	—
	Total	3	373

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Acquisitions	Acquisitions
	MD Office Solutions (2015)
	On March 5, 2015, we entered into an Agreement of Merger and Plan of Reorganization (the Merger Agreement) to acquire MD Office Solutions (MD Office). MD office is a provider of in-office nuclear cardiology imaging in the northern and central California regions. The acquisition expands the geographical region in which we are able to provide our in-office nuclear cardiology imaging services.
	Total consideration related to the Merger Agreement paid to the sellers was 610,000 shares of common stock of Digirad Corporation, with a total value at closing of $2,684,000, as well as settlement of a $15,000 accounts receivable balance owed to the Company. The Company issued new shares for the consideration. In addition, there is an earn-out opportunity of up to $400,000 in cash over approximately three years based on the MD Office business meeting certain earnings before interest, taxes, depreciation, and amortization (EBITDA) milestones. The sellers will receive fifty percent of the EBITDA generated by the MD Office business in excess of the EBITDA milestone amounts, which are $650,000 for each of the annual periods ending December 31, 2015, 2016, and 2017, with the target for 2015 being prorated based on the close date.
	At March 31, 2015, we have estimated the fair value of the contingent earn-out opportunity to be $6,000. The earn-out opportunity is estimated based on the expected performance of the business over the period from the acquisition date through December 31, 2017, utilizing an income approach. It is reasonably possible that our estimate of the earn-out potential could change in the near term. Any adjustment in the estimated earn-out opportunity until settled will be recorded as a gain or loss to current operations in the period the estimate changes.
	The Merger Agreement is also subject to a post-closing purchase price adjustment based on the final working capital balance, as defined in the Merger Agreement, as well as a Registration Rights Agreement related to the common shares provided to the sellers as part of the consideration.
	The following table summarizes the preliminary purchase price allocation recognized as of the close date of March 5, 2015:
	(in thousands)		Allocation of purchase price
	Assets
	Current assets:
	Cash and cash equivalents		$	3
	Accounts receivable, net		457
	Other current assets		32
	Total current assets		492
	Property and equipment, net		481
	Intangible assets, net		1,007
	Goodwill		1,552
	Other assets		24
	Total assets		$	3,556
	Liabilities
	Current liabilities:
	Accounts payable		$	149
	Accrued compensation		81
	Other accrued liabilities		33
	Total current liabilities		263
	Deferred tax liability		588
	Other liabilities		6
	Total liabilities		$	857
	The goodwill recognized as part of the transaction primarily represents synergies between Digirad and MD Office that were not separately identified as part of the acquisition valuation process. MD Office activities are included within the Diagnostic Services reportable segment. The resulting goodwill from the acquisition is not deductible for federal and state tax reporting purposes.
	The following table summarizes the fair value of acquired identifiable intangible assets as of the acquisition date:
	(in thousands)	Weighted Average Useful Lives (in years)		Fair Value
	Customer relationships	7		$	639
	Trademarks	5		187
	Covenants not to compete	5		181
	Total intangible assets acquired, excluding goodwill			$	1,007
	As of March 31, 2015, the final working capital adjustment has not been completed, and therefore the accounting for the acquisition is incomplete. We have estimated the working capital adjustment at March 5, 2015 at approximately $7,000 due to the sellers, which is included in the estimated consideration above. It is reasonably possible this estimated working capital adjustment could change based on the final agreed upon amount pursuant to the Merger Agreement. Any adjustment to this amount will affect the purchase consideration, and therefore the allocation of the purchase price, with the majority of any such adjustment likely affecting the recorded goodwill amount. We anticipate closing the measurement period by June 30, 2015.
	The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2014. In deriving the proforma results, we utilized the historical operating results of MD Office and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2014.
			Three Months Ended March 31,
	(in thousands)		2015			2014
	Revenues		$	14,406		$	13,751
	Net income (loss)		$	895		$	(324	)
	Included within our consolidated operating results for the period ending March 31, 2015 are MD Office operations for the period March 6, 2015 through March 31, 2015 as follows:
			March 6, 2015 - March 31, 2015
	Revenues		$	216
	Net loss		$	(106	)
	Included within the results for MD Office is approximately $136,000 of transaction costs related to the acquisition. These costs are classified as general and administrative expenses in the consolidated statements of comprehensive income (loss).
	Telerhythmics, LLC (2014)
	On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC (Telerhythmics), a provider of 24-hour cardiac monitoring services. Telerhythmics and Digirad each have a very similar customer base, yet with only minor overlaps in current customers. We believe this similar customer base will allow us to leverage each company’s strengths to grow sales and also diversify Digirad's service offerings.
	We paid to the sellers of the membership interest (the Sellers) aggregate up-front consideration of $3.4 million and assumed approximately $131,000 in debt. In addition, there is an aggregate earn-out opportunity of up to $501,000 from the period March 14, 2014 through December 31, 2016 based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones. The Sellers will receive fifty percent (50%) of the EBITDA generated by the Telerhythmics business in excess of the EBITDA milestone amounts, which are as follows:
	•	$415,000 of EBITDA for the period from the closing date through December 31, 2014;
	•	$825,000 of EBITDA for the period from January 1, 2015 through December 31, 2015; and
	•	$825,000 of EBITDA for the period from January 1, 2016 through December 31, 2016.
	At March 31, 2015, we have estimated the fair value of the contingent earn-out opportunity to be $229,000. The earn-out opportunity is estimated based on the expected performance of the business over the period from January 1, 2015 through December 31, 2016, utilizing an income approach. No earn-out consideration was earned by the Sellers for the period from the closing date through December 31, 2014. It is reasonably possible that our estimate of the earn-out potential could change in the near term. Any adjustment in the estimated earn-out opportunity until settled will be recorded as a gain or loss to current operations in the period the estimate changes.
	The allocation of the purchase price to the assets acquired and liabilities assumed on the acquisition date was as follows:
	(in thousands)		Allocation of purchase price
	Assets
	Current assets:
	Accounts receivable, net		$	256
	Other current assets		34
	Total current assets		290
	Property and equipment, net		290
	Intangible assets, net		2,580
	Goodwill		1,153
	Total assets		$	4,313
Liabilities
Current liabilities:
Accounts payable		$	36
Accrued compensation		169
Other accrued liabilities		356
Current portion of long-term debt		131
Total current liabilities		692
Other liabilities		174
Total liabilities		$	866
The long-term debt was subsequently paid in full on March 28, 2014.
The goodwill recognized as part of the transaction primarily represents synergies between Digirad and Telerhythmics that were not separately identified as part of the acquisition valuation process. Telerhythmics activities are considered their own operating segment, which is aggregated into our Diagnostic Services reportable segment. The resulting goodwill from the acquisition is expected to be deductible for federal and state tax reporting purposes.
The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2013. In deriving the proforma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013.
		Three Months Ended March 31,
(in thousands)		2014			2013
Revenues		$	14,152		$	12,959
Net income (loss)		$	26		$	(2,534	)

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories
	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis.
	(in thousands)	March 31,			December 31,
		2015			2014
	Inventories:
	Raw materials	$	2,385		$	2,439
	Work-in-process	1,784			2,560
	Finished goods	1,203			558
	Total inventories	5,372			5,557
	Less reserve for excess and obsolete inventories	(1,715		)	(1,913		)
	Total inventories, net	$	3,657		$	3,644

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment
	(in thousands)	March 31,			December 31,
		2015			2014
	Property and equipment:
	Machinery and equipment	$	23,962		$	23,412
	Computer hardware and software	3,079			2,917
	Leasehold improvements	583			571
	Total property and equipment	27,624			26,900
	Less accumulated depreciation	(22,427		)	(22,134		)
	Total property and equipment, net	$	5,197		$	4,766

Intangibles_and_Goodwill

Intangibles and Goodwill	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles and Goodwill	Intangibles and Goodwill
			March 31, 2015
	(in thousands)		Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with indefinite useful lives:
	Goodwill (2)		Indefinite	$	2,889	$	—		$	2,889
	Intangible assets with finite useful lives:
	Customer relationships (2)		8.2	$	5,489	$	(2,982	)	$	2,507
	Trademarks (2)		8	787		(72		)	715
	Patents		13.4	141		(118		)	23
	Covenants not to compete (2)		5	251		(17		)	234
	Total intangible assets, net			$	6,668	$	(3,189	)	$	3,479
			December 31, 2014
			Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with infinite useful lives:
	Goodwill		Indefinite	$	1,337	$	—		$	1,337
	Intangible assets with finite useful lives:
	Customer relationships		8.6	$	4,850	$	(2,904	)	$	1,946
	Trademarks		9	600		(53		)	547
	Patents		13.2	141		(116		)	25
	Covenants not to compete		5	70		(11		)	59
	Total intangible assets, net			$	5,661	$	(3,084	)	$	2,577
	-1	Amortization expense for intangible assets, net was $0.1 million for the three months ended March 31, 2015 and 2014. Estimated amortization expense for intangible assets for the remainder of 2015 is $0.4 million, for 2016 is $0.5 million, for 2017 is $0.5 million, for 2018 is $0.5 million, for 2019 is $0.4 million, for 2020 is $0.4 million, and thereafter is $0.8 million.
	-2	As a result of our acquisition of MD Office on March 5, 2015, we recorded certain intangible assets (See Note 3).

Restructuring_Charges

Restructuring Charges	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring Charges
	Facilities restructuring initiative
	On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the Facilities restructuring initiative). This action was undertaken as the facility had excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations.
	As a result of the Facilities restructuring initiative, we incurred a total of $0.7 million in restructuring charges which occurred solely during fiscal year 2014. Facilities restructuring charges of $0.4 million were incurred during the three months ended March 31, 2014. No Facilities restructuring charges were incurred during the three months ended March 31, 2015. The charges were comprised of lease termination, moving, and other related costs. All Facilities restructuring charges were included in the Diagnostic Imaging segment. Restructuring liabilities and associated charges were measured at fair value as incurred.

Financial_Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Financial Instruments	Financial Instruments
	Assets and Liabilities Measured at Fair Value on a Recurring Basis. The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2015 and December 31, 2014.
		Fair Value as of March 31, 2015
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	7,048			$	—			$	7,048
	Liabilities:
	Acquisition related contingent consideration	$	—			$	—			$	235			$	235
		Fair Value as of December 31, 2014
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	7,935			$	—			$	7,935
	Liabilities:
	Acquisition related contingent consideration	$	—			$	—			$	229			$	229
	The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, and/or offers. We did not reclassify any investments between levels in the fair value hierarchy during the three months ended March 31, 2015.
	The acquisition related contingent consideration is related to our acquisition of Telerhythmics on March 13, 2014 and acquisition of MD Office on March 5, 2015 (See Note 3).  We reassess the fair value of the contingent consideration to be settled in cash related to our acquisitions of Telerhythmics and MD Office on a quarterly basis using the income approach, which is a Level 3 measurement. There was no change to the fair value of the acquisition related contingent consideration during the three months ended March 31, 2015, other than the addition of $6,000 of contingent consideration related to the MD Office acquisition. Significant assumptions used in the measurement include probabilities of achieving the EBITDA milestones.
	Securities Available-for-Sale
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income (loss). The realized gains and losses on these sales were minimal for the three months ended March 31, 2015 and 2014.
	The following table sets forth the composition of securities available-for-sale as of March 31, 2015 and December 31, 2014.
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of March 31, 2015 (in thousands)	Years						Gains				Losses
	Corporate debt securities	Less than 1 year		$	4,489			$	1			$	(2	)		$	4,488
	Corporate debt securities	1-3 years		2,564				1				(5		)		2,560
				$	7,053			$	2			$	(7	)		$	7,048
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of December 31, 2014 (in thousands)	Years						Gains				Losses
	Corporate debt securities	Less than 1 year		$	4,650			$	—			$	(5	)		$	4,645
	Corporate debt securities	1-3 years		3,304				—				(14		)		3,290
				$	7,954			$	—			$	(19	)		$	7,935

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Other matters. In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	For the quarter ended March 31, 2015, we recorded an income tax benefit of approximately $0.6 million related to the release of valuation allowance associated with the acquisition of MD Office.  The valuation allowance release occurred when we recorded an increase to our deferred tax liability balance as a result of book and tax basis differences in acquired fixed, intangible and other assets of MD Office.
	As of December 31, 2014, we had unrecognized tax benefits of approximately $1.6 million. Included in the unrecognized tax benefits were $1.3 million of tax benefits that, if recognized, would reduce our annual effective tax rate, subject to the valuation allowance.
	We assess the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was our cumulative profitability over the three-year period ended March 31, 2015. Such objective evidence limits the ability to consider other subjective evidence such as our projections for future income. On the basis of this evaluation, as of March 31, 2015, a valuation allowance has been recorded as we cannot conclude that it is more likely than not that the existing deferred tax assets will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence such as our projected future income.
	We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2009; however, our net operating loss and research credit carry-forwards arising prior to that year are subject to adjustment. It is our policy to recognize interest expense and penalties related to income tax matters as a component of income tax expense.

Segments

Segments	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segments	Segments
	Our reporting segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment.
	On March 5, 2015, we acquired MD Office (See Note 3). As part of the acquisition, we evaluated MD Office's business operations, both on a quantitative and qualitative basis, and determined its business operations appropriately met the criteria to be aggregated with our Diagnostic Services business in accordance with the authoritative accounting guidance for segment reporting.
	The financial results below for the three months ended March 31, 2015 include the financial results of MD Office for the period since the acquisition date of March 5, 2015.
		Three Months Ended March 31,
	(in thousands)	2015			2014
	Gross profit by segment:
	Diagnostic Services	$	2,058		$	2,021
	Diagnostic Imaging	1,590			1,421
	Condensed consolidated gross profit	$	3,648		$	3,442
	Income (loss) from operations by segment:
	Diagnostic Services	$	(537	)	$	(333	)
	Diagnostic Imaging (1)	702			178
	Condensed consolidated income (loss) from operations	$	165		$	(155	)
	Depreciation and amortization:
	Diagnostic Services	$	417		$	375
	Diagnostic Imaging	71			78
	Condensed consolidated depreciation and amortization	$	488		$	453
	(in thousands)	31-Mar-15			31-Dec-14
	Identifiable assets by segment:
	Diagnostic Services	$	21,596		$	18,724
	Diagnostic Imaging	23,274			23,177
	Condensed consolidated assets	$	44,870		$	41,901
	(1) Included in the Diagnostic Imaging income from operations for the three months ended March 31, 2014, are approximately $0.4 million of charges associated with our Facilities restructuring initiative (See Note 7).

Subsequent_Event

Subsequent Event	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Event	Subsequent Events
	On April 30, 2015, the Company announced a cash dividend of $0.05 per share payable on May 27, 2015 to shareholders of record on May 13, 2015.

Financial_Instruments_policies

Financial Instruments (policies)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments, Policy	The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, and/or offers.
Securities Available-for-sale, Policy	Securities Available-for-Sale
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income (loss).

Schedule_of_Earnings_Per_Share

Schedule of Earnings Per Share, Basic and Diluted (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share, Basic and Diluted [Abstract]
Schedule of Earnings (Loss) Per Share, Basic and Diluted	The following table sets forth the reconciliation of shares used to compute basic and diluted net income (loss) per share for the periods indicated:
		Three Months Ended March 31,
	(shares in thousands)	2015	2014
	Weighted average shares outstanding - basic	18,803	18,518
	Dilutive potential common stock outstanding:
	Stock options	474	—
	Restricted stock units	14	—
	Weighted average shares outstanding - diluted	19,291	18,518
Schedule of Antidilutive Securities Excluded from Computation of Earnings (Loss) Per Share	The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net income (loss) per share because their effect was anti-dilutive:
		Three Months Ended March 31,
	(shares in thousands)	2015	2014
	Stock options	3	373
	Restricted stock units	—	—
	Total	3	373

Acquisitions_Tables

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2015
MD Office [Member]
Business Acquisition [Line Items]
Schedule of Preliminary Allocation of Purchase Price	The following table summarizes the preliminary purchase price allocation recognized as of the close date of March 5, 2015:
	(in thousands)		Allocation of purchase price
	Assets
	Current assets:
	Cash and cash equivalents		$	3
	Accounts receivable, net		457
	Other current assets		32
	Total current assets		492
	Property and equipment, net		481
	Intangible assets, net		1,007
	Goodwill		1,552
	Other assets		24
	Total assets		$	3,556
	Liabilities
	Current liabilities:
	Accounts payable		$	149
	Accrued compensation		81
	Other accrued liabilities		33
	Total current liabilities		263
	Deferred tax liability		588
	Other liabilities		6
	Total liabilities		$	857
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	The following table summarizes the fair value of acquired identifiable intangible assets as of the acquisition date:
	(in thousands)	Weighted Average Useful Lives (in years)		Fair Value
	Customer relationships	7		$	639
	Trademarks	5		187
	Covenants not to compete	5		181
	Total intangible assets acquired, excluding goodwill			$	1,007
Schedule of Estimated Proforma Results	The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2014. In deriving the proforma results, we utilized the historical operating results of MD Office and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2014.
			Three Months Ended March 31,
	(in thousands)		2015			2014
	Revenues		$	14,406		$	13,751
	Net income (loss)		$	895		$	(324	)
Consolidated Operating Results of Acquired Entity	Included within our consolidated operating results for the period ending March 31, 2015 are MD Office operations for the period March 6, 2015 through March 31, 2015 as follows:
			March 6, 2015 - March 31, 2015
	Revenues		$	216
	Net loss		$	(106	)
Telerhythmics [Member]
Business Acquisition [Line Items]
Schedule of Preliminary Allocation of Purchase Price	he allocation of the purchase price to the assets acquired and liabilities assumed on the acquisition date was as follows:
	(in thousands)		Allocation of purchase price
	Assets
	Current assets:
	Accounts receivable, net		$	256
	Other current assets		34
	Total current assets		290
	Property and equipment, net		290
	Intangible assets, net		2,580
	Goodwill		1,153
	Total assets		$	4,313
	Liabilities
	Current liabilities:
	Accounts payable		$	36
	Accrued compensation		169
	Other accrued liabilities		356
	Current portion of long-term debt		131
	Total current liabilities		692
	Other liabilities		174
	Total liabilities		$	866
Schedule of Estimated Proforma Results	The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2013. In deriving the proforma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013.
			Three Months Ended March 31,
	(in thousands)		2014			2013
	Revenues		$	14,152		$	12,959
	Net income (loss)		$	26		$	(2,534	)

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis.
	(in thousands)	March 31,			December 31,
		2015			2014
	Inventories:
	Raw materials	$	2,385		$	2,439
	Work-in-process	1,784			2,560
	Finished goods	1,203			558
	Total inventories	5,372			5,557
	Less reserve for excess and obsolete inventories	(1,715		)	(1,913		)
	Total inventories, net	$	3,657		$	3,644

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment
	(in thousands)	March 31,			December 31,
		2015			2014
	Property and equipment:
	Machinery and equipment	$	23,962		$	23,412
	Computer hardware and software	3,079			2,917
	Leasehold improvements	583			571
	Total property and equipment	27,624			26,900
	Less accumulated depreciation	(22,427		)	(22,134		)
	Total property and equipment, net	$	5,197		$	4,766

Intangibles_and_Goodwill_Table

Intangibles and Goodwill (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill
			March 31, 2015
	(in thousands)		Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with indefinite useful lives:
	Goodwill (2)		Indefinite	$	2,889	$	—		$	2,889
	Intangible assets with finite useful lives:
	Customer relationships (2)		8.2	$	5,489	$	(2,982	)	$	2,507
	Trademarks (2)		8	787		(72		)	715
	Patents		13.4	141		(118		)	23
	Covenants not to compete (2)		5	251		(17		)	234
	Total intangible assets, net			$	6,668	$	(3,189	)	$	3,479
			December 31, 2014
			Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with infinite useful lives:
	Goodwill		Indefinite	$	1,337	$	—		$	1,337
	Intangible assets with finite useful lives:
	Customer relationships		8.6	$	4,850	$	(2,904	)	$	1,946
	Trademarks		9	600		(53		)	547
	Patents		13.2	141		(116		)	25
	Covenants not to compete		5	70		(11		)	59
	Total intangible assets, net			$	5,661	$	(3,084	)	$	2,577
	-1	Amortization expense for intangible assets, net was $0.1 million for the three months ended March 31, 2015 and 2014. Estimated amortization expense for intangible assets for the remainder of 2015 is $0.4 million, for 2016 is $0.5 million, for 2017 is $0.5 million, for 2018 is $0.5 million, for 2019 is $0.4 million, for 2020 is $0.4 million, and thereafter is $0.8 million.
	-2	As a result of our acquisition of MD Office on March 5, 2015, we recorded certain intangible assets

Financial_Instruments_Tables

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2015 and December 31, 2014.
		Fair Value as of March 31, 2015
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	7,048			$	—			$	7,048
	Liabilities:
	Acquisition related contingent consideration	$	—			$	—			$	235			$	235
		Fair Value as of December 31, 2014
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	7,935			$	—			$	7,935
	Liabilities:
	Acquisition related contingent consideration	$	—			$	—			$	229			$	229
Available-for-sale Securities	The following table sets forth the composition of securities available-for-sale as of March 31, 2015 and December 31, 2014.
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of March 31, 2015 (in thousands)	Years						Gains				Losses
	Corporate debt securities	Less than 1 year		$	4,489			$	1			$	(2	)		$	4,488
	Corporate debt securities	1-3 years		2,564				1				(5		)		2,560
				$	7,053			$	2			$	(7	)		$	7,048
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of December 31, 2014 (in thousands)	Years						Gains				Losses
	Corporate debt securities	Less than 1 year		$	4,650			$	—			$	(5	)		$	4,645
	Corporate debt securities	1-3 years		3,304				—				(14		)		3,290
				$	7,954			$	—			$	(19	)		$	7,935

Segments_Tables

Segments (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The financial results below for the three months ended March 31, 2015 include the financial results of MD Office for the period since the acquisition date of March 5, 2015.
		Three Months Ended March 31,
	(in thousands)	2015			2014
	Gross profit by segment:
	Diagnostic Services	$	2,058		$	2,021
	Diagnostic Imaging	1,590			1,421
	Condensed consolidated gross profit	$	3,648		$	3,442
	Income (loss) from operations by segment:
	Diagnostic Services	$	(537	)	$	(333	)
	Diagnostic Imaging (1)	702			178
	Condensed consolidated income (loss) from operations	$	165		$	(155	)
	Depreciation and amortization:
	Diagnostic Services	$	417		$	375
	Diagnostic Imaging	71			78
	Condensed consolidated depreciation and amortization	$	488		$	453
Reconciliation of Assets from Segment to Consolidated
	(in thousands)	31-Mar-15			31-Dec-14
	Identifiable assets by segment:
	Diagnostic Services	$	21,596		$	18,724
	Diagnostic Imaging	23,274			23,177
	Condensed consolidated assets	$	44,870		$	41,901
	(1) Included in the Diagnostic Imaging income from operations for the three months ended March 31, 2014, are approximately $0.4 million of charges associated with our Facilities restructuring initiative (See Note 7).

The_Company_Details

The Company (Details)	3 Months Ended
	Mar. 31, 2015
	segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	2

Basic_and_Diluted_Net_Income_L1

Basic and Diluted Net Income (Loss) Per Share (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share, Basic and Diluted [Abstract]
Weighted average shares outstanding – basic	18,803	18,518
Dilutive potential common stock outstanding:
Stock options	474	0
Restricted stock units	14	0
Weighted average shares outstanding – diluted	19,291	18,518
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share	3	373
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share	3	373
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share	0	0

Acquisitions_Details

Acquisitions (Details) (USD $)	3 Months Ended			0 Months Ended	1 Months Ended		0 Months Ended	12 Months Ended
Share data in Thousands, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014	Mar. 05, 2015	Mar. 31, 2015		Mar. 13, 2014	Dec. 31, 2014
Business Acquisition, Contingent Consideration [Line Items]
Stock Issued During Period, Value, Acquisitions	$2,684,000		$0
Net loss	745,000		-148,000
Finite-lived Intangible Assets Acquired	3,479,000	[1]			3,479,000	[1]		2,577,000
MD Office [Member]
Business Acquisition, Contingent Consideration [Line Items]
Stock Issued During Period, Shares, Acquisitions				610
Stock Issued During Period, Value, Acquisitions				2,684,000
business combination, settlement of accounts receivable owed to the Company				15,000
Aggregate earn-out opportunity				400,000
Percentage of EBITDA to be received by sellers (percent)				50.00%
Estimated fair value of contingent earn-out opportunity	6,000				6,000
Cash and cash equivalents				3,000
Accounts receivable, net				457,000
Other current assets				32,000
Total current assets				492,000
Property and equipment, net				481,000
Intangible assets, net				1,007,000
Goodwill				1,552,000
Other assets				24,000
Total assets				3,556,000
Accounts payable				149,000
Accrued compensation				81,000
Other accrued liabilities				33,000
Total current liabilities				263,000
Deferred tax liability				588,000
Other liabilities				6,000
Total liabilities				857,000
Revenues	14,406,000		13,751,000
Net income (loss)	895,000		-324,000
Net loss					-106,000
Finite-lived Intangible Assets Acquired				1,007,000
Business Acquisition, Expected Working Capital Adjustment	7,000				7,000
Revenue, Net					216,000
Transaction costs included within results for Telerhythmics	136,000				136,000
Telerhythmics [Member]
Business Acquisition, Contingent Consideration [Line Items]
Aggregate earn-out opportunity							501,000
Percentage of EBITDA to be received by sellers (percent)							50.00%
Estimated fair value of contingent earn-out opportunity	229,000				229,000
Accounts receivable, net	256,000				256,000
Other current assets	34,000				34,000
Total current assets	290,000				290,000
Property and equipment, net	290,000				290,000
Intangible assets, net	2,580,000				2,580,000
Goodwill	1,153,000				1,153,000
Total assets	4,313,000				4,313,000
Accounts payable	36,000				36,000
Accrued compensation	169,000				169,000
Other accrued liabilities	356,000				356,000
Total current liabilities	692,000				692,000
Other liabilities	174,000				174,000
Total liabilities	866,000				866,000
Revenues	14,152,000		12,959,000
Net income (loss)	26,000		-2,534,000
Membership interest acquired in business acquisition (percent)							100.00%
Aggregate upfront consideration paid							3,400,000
Debt assumed in business acquisition	131,000				131,000		131,000
Year one to Year three [Member] | MD Office [Member]
Business Acquisition, Contingent Consideration [Line Items]
Aggregate earn-out opportunity				650,000
Year one [Member] | Telerhythmics [Member]
Business Acquisition, Contingent Consideration [Line Items]
Aggregate earn-out opportunity							415,000
Year two [Member] | Telerhythmics [Member]
Business Acquisition, Contingent Consideration [Line Items]
Aggregate earn-out opportunity							825,000
Year three [Member] | Telerhythmics [Member]
Business Acquisition, Contingent Consideration [Line Items]
Aggregate earn-out opportunity							825,000
Customer Relationships [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life	8 years 2 months 12 days	[2]						8 years 7 months 6 days
Finite-lived Intangible Assets Acquired	2,507,000	[1],[2]			2,507,000	[1],[2]		1,946,000
Customer Relationships [Member] | MD Office [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years
Finite-lived Intangible Assets Acquired				639,000
Trademarks [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years 11 months 19 days	[2]						9 years
Finite-lived Intangible Assets Acquired	715,000	[1],[2]			715,000	[1],[2]		547,000
Trademarks [Member] | MD Office [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Finite-lived Intangible Assets Acquired				187,000
Noncompete Agreements [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years	[2]						5 years
Finite-lived Intangible Assets Acquired	234,000	[1],[2]			234,000	[1],[2]		59,000
Noncompete Agreements [Member] | MD Office [Member]
Business Acquisition, Contingent Consideration [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Finite-lived Intangible Assets Acquired				$181,000
[1]	mortization expense for intangible assets, net was $0.1 million for the three months ended March 31, 2015 and 2014. Estimated amortization expense for intangible assets for the remainder of 2015 is $0.4 million, for 2016 is $0.5 million, for 2017 is $0.5 million, for 2018 is $0.5 million, for 2019 is $0.4 million, for 2020 is $0.4 million, and thereafter is $0.8 million.
[2]	.

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$2,385	$2,439
Work-in-process	1,784	2,560
Finished goods	1,203	558
Total inventories	5,372	5,557
Less reserve for excess and obsolete inventories	-1,715	-1,913
Total inventories, net	$3,657	$3,644

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	$27,624	$26,900
Less accumulated depreciation	-22,427	-22,134
Total property and equipment, net	5,197	4,766
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	23,962	23,412
Computer hardware and software [Member]
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	3,079	2,917
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	$583	$571

Intangibles_and_Goodwill_Detai

Intangibles and Goodwill (Details) (USD $)	3 Months Ended			12 Months Ended
	Mar. 31, 2015		Mar. 31, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Goodwill, Gross	$2,889,000	[1]		$1,337,000
Goodwill	2,889,000	[1],[2]		1,337,000
Finite-Lived Intangible Assets, Gross	6,668,000			5,661,000
Finite-Lived Intangible Assets, Accumulated Amortization	-3,189,000			-3,084,000
Finite-Lived Intangible Assets, Net	3,479,000	[2]		2,577,000
Amortization of intangible assets	105,000		66,000
Finite-Lived Intangible Assets, Amortization Expense, 2015	400,000
Finite-Lived Intangible Assets, Amortization Expense, 2016	500,000
Finite-Lived Intangible Assets, Amortization Expense, 2017	500,000
Finite-Lived Intangible Assets, Amortization Expense, 2018	500,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four	400,000
Finite-Lived Intangible Assets, Amortization Expense, Year Five	400,000
Finite-Lived Intangible Assets, Amortization Expense, 2019 and thereafter	800,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	8 years 2 months 12 days	[1]		8 years 7 months 6 days
Finite-Lived Intangible Assets, Gross	5,489,000	[1]		4,850,000
Finite-Lived Intangible Assets, Accumulated Amortization	-2,982,000	[1]		-2,904,000
Finite-Lived Intangible Assets, Net	2,507,000	[1],[2]		1,946,000
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years 11 months 19 days	[1]		9 years
Finite-Lived Intangible Assets, Gross	787,000	[1]		600,000
Finite-Lived Intangible Assets, Accumulated Amortization	-72,000	[1]		-53,000
Finite-Lived Intangible Assets, Net	715,000	[1],[2]		547,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	13 years 5 months 8 days			13 years 2 months 12 days
Finite-Lived Intangible Assets, Gross	141,000			141,000
Finite-Lived Intangible Assets, Accumulated Amortization	-118,000			-116,000
Finite-Lived Intangible Assets, Net	23,000	[2]		25,000
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years	[1]		5 years
Finite-Lived Intangible Assets, Gross	251,000	[1]		70,000
Finite-Lived Intangible Assets, Accumulated Amortization	-17,000	[1]		-11,000
Finite-Lived Intangible Assets, Net	$234,000	[1],[2]		$59,000
[1]	.
[2]	mortization expense for intangible assets, net was $0.1 million for the three months ended March 31, 2015 and 2014. Estimated amortization expense for intangible assets for the remainder of 2015 is $0.4 million, for 2016 is $0.5 million, for 2017 is $0.5 million, for 2018 is $0.5 million, for 2019 is $0.4 million, for 2020 is $0.4 million, and thereafter is $0.8 million.

Restructuring_Charges_Faciliti

Restructuring Charges - Facilities Restructuring Initiative (Details) (Facilities Restructuring Initiative [Member], USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2014	Jan. 27, 2014	Jan. 23, 2014
			sqft	sqft
Facilities Restructuring Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Area of Real Estate Property			47,000	21,300
Restructuring and Related Cost, Incurred Cost	$0.40	$0.70

Financial_Instruments_Assets_a

Financial Instruments Assets and Liabilities at Fair Value on a Recurring Basis (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure	$235	$229
Corporate Debt Securities [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	7,048	7,935
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure	0	0
Level 1 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	0	0
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure	0	0
Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	7,048	7,935
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure	235	229
Level 3 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	$0	$0

Financial_Instruments_Securiti

Financial Instruments Securities Available for Sale (Details) (Corporate Debt Securities [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$7,053	$7,954
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	2	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	-7	-19
Fair Value	7,048	7,935
Less than 1 year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	4,489	4,650
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	1	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	-2	-5
Fair Value	4,488	4,645
1-3 years [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	2,564	3,304
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	1	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	-5	-14
Fair Value	$2,560	$3,290

Income_Tax_Details

Income Tax (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income tax benefit	$580,000	($2,000)
Unrecognized tax benefits			1,600,000
Unrecognized tax benefits that would impact effective tax rate			$1,300,000

Segments_Details

Segments (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014
Segment Reporting Information [Line Items]
Gross profit by segment	$3,648		$3,442
Income (loss) from operations by segment	165		-155
Depreciation and amortization	488		453
Restructuring charges	0		441
Diagnostic Services [Member]
Segment Reporting Information [Line Items]
Gross profit by segment	2,058		2,021
Income (loss) from operations by segment	-537		-333
Depreciation and amortization	417		375
Diagnostic Imaging [Member]
Segment Reporting Information [Line Items]
Gross profit by segment	1,590		1,421
Income (loss) from operations by segment	702	[1]	178	[1]
Depreciation and amortization	$71		$78
[1]	Included in the Diagnostic Imaging income from operations for the three months ended March 31, 2014, are approximately $0.4 million of charges associated with our Facilities restructuring initiative (See Note 7).

Segments_Asset_by_Segment_Deta

Segments Asset by Segment Detail (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]
Identifiable assets by segment	$44,870	$41,901
Diagnostic Services [Member]
Segment Reporting Information [Line Items]
Identifiable assets by segment	21,596	18,724
Diagnostic Imaging [Member]
Segment Reporting Information [Line Items]
Identifiable assets by segment	$23,274	$23,177

Subsequent_Event_Detail_Detail

Subsequent Event Detail (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Apr. 30, 2015
Subsequent Event [Line Items]
Dividends declared per common share (in US$ per share)	$0.05	$0.05
Subsequent Event [Member]
Subsequent Event [Line Items]
Dividends declared per common share (in US$ per share)			$0.05